Jounce Therapeutics to Participate in a Virtual Fireside Chat at Cowen 2020 IO Next Summit
Jounce Therapeutics, Inc. (NASDAQ: JNCE) announced participation in a fireside chat at the Cowen 2020 IO Next Summit on November 13, 2020, at 12:15 p.m. ET.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Jounce Therapeutics, Inc. (NASDAQ: JNCE) announced participation in a fireside chat at the Cowen 2020 IO Next Summit on November 13, 2020, at 12:15 p.m. ET. A live webcast of the session will be available on the company's website, with a replay archived for 30 days. Jounce focuses on developing novel cancer immunotherapies, including its lead candidate, vopratelimab, currently in the SELECT Phase 2 trial. The company is also advancing JTX-4014 and JTX-8064, and has licensed JTX-1811 to Gilead Sciences. For details, visit www.jouncetx.com.
Details
News Market Reaction – JNCE
The recorded move for JNCE in the trading session of this news was +4.14%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
CAMBRIDGE, Mass., Nov. 09, 2020 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, today announced that Jounce management will participate in a fireside chat at the Cowen 2020 IO Next Summit on Friday, November 13, 2020 at 12:15 p.m. ET.
A live webcast of the presentation will be available by visiting "Events & Presentations" in the Investors and Media section of the company's website at www.jouncetx.com. A replay of the webcast will be archived for 30 days following the presentation.
About Jounce Therapeutics:
Jounce Therapeutics, Inc. is a clinical-stage immunotherapy company dedicated to transforming the treatment of cancer by developing therapies that enable the immune system to attack tumors and provide long-lasting benefits to patients through a biomarker-driven approach. Jounce currently has multiple development stage programs ongoing while simultaneously advancing additional early-stage assets from its robust discovery engine based on its Translational Science Platform. Jounce’s most advanced product candidate, vopratelimab, is a monoclonal antibody that binds to and activates ICOS, and is currently being studied in the SELECT Phase 2 trial. JTX-4014 is a PD-1 inhibitor intended for combination use in the SELECT trial and with Jounce’s broader pipeline. Jounce’s next development stage product candidate, JTX-8064, is a LILRB2 (ILT4) receptor antagonist shown to reprogram immune-suppressive tumor associated macrophages to an anti-tumor state. A Phase 1 trial evaluating JTX-8064 is planned to begin enrollment in the fourth quarter of 2020. Additionally, Jounce exclusively licensed worldwide rights to JTX-1811, a monoclonal antibody targeting CCR8 and designed to selectively deplete T regulatory cells in the tumor microenvironment, to Gilead Sciences, Inc. For more information, please visit www.jouncetx.com.
Investor and Media Contacts:
Malin Deon
Jounce Therapeutics, Inc.
+1-857-259-3843
mdeon@jouncetx.com
Mark Yore
Jounce Therapeutics, Inc.
+1-857-200-1255
myore@jouncetx.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.